Sumatridex

/ Dexcel

Adults: Sumatriptan is indicated for the acute intermittent treatment of migraine. It should not be used prophylactically.
It is advisable that Sumatriptan be given as early as possible after the onset of migraine attack but it is equally effective at whatever stage of the attack it is administered.
The recommended dose of oral Sumatriptan is a single 50mg caplet. Some patients may require 100mg.
If the patient has responded to the first dose but the symptoms recur a second dose may be given in the next 24 hours provided that there is a minimum interval of two hours between the two doses. No more than 300mg should be taken in any 24 hour period.
Patients who do not respond to the prescribed dose of Sumatriptan should not take a second dose for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. Sumatriptan may be taken for subsequent attacks.
Sumatriptan is recommended as monotherapy for the acute treatment of migraine and should not be given concomitantly with ergotamine or derivatives of ergotamine (including methysergide).
Paediatric population: The efficacy and safety of Sumatriptan in children aged less than 10 years have not been established. No clinical data are available in this age group.
The efficacy and safety of Sumatriptan in children 10 to 17 years of age have not been demonstrated in the clinical trials performed in this age group. Therefore the use of Sumatriptan in children 10 to 17 years of age is not recommended.
Elderly (Over 65 years of age): Experience of the use of Sumatriptan in patients aged over 65 years is limited. The pharmacokinetics do not differ significantly from a younger population but until further clinical data are available, the use of Sumatriptan in patients aged over 65 years is not recommended.

Sumatridex caplets are indicated for the acute relief of migraine attacks, with or without aura.
Sumatridex should only be used where there is a clear diagnosis of migraine.

Hypersensitivity to sumatriptan or to any of the excipients.
Sumatriptan should not be given to patients who have had myocardial infarction or have ischaemic heart disease, coronary vasospasm (Prinzmetal’s angina), peripheral vascular disease or patients who have symptoms or sign consistent with ischaemic heart disease.
Sumatriptan should not be administered to patients with a history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA).
Sumatriptan should not be administered to patients with severe hepatic impairment.
The use of sumatriptan in patients with moderate and severe hypertension and mild uncontrolled hypertension is contraindicated.
The concomitant administration of ergotamine or derivatives of ergotamine (including methysergide) or any triptan/5-hydroxytryptamine1 (5-HT1) receptor agonist with sumatriptan is contraindicated.
Concurrent administration of monoamine oxidase inhibitors and sumatriptan is contraindicated. Sunatridex Caplets must not be used within two weeks of discontinuation of therapy with monoamine oxidase inhibitors.